Sugi Predict

Sugi Predict / Compounds / SCHEMBL19749932

SCHEMBL19749932

SCHEMBL19749932

NC[C@H](NCC(=O)OCc1ccccc1)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ SLC15A1 P46059 2/20 0.45
▸ CYP1A2 P05177 2/20 0.43
▸ CYP2C9 P11712 2/20 0.43
▸ CYP2C19 P33261 2/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ ABCC3 O15438 1/20 0.43
▸ NR1I2 O75469 1/20 0.43
▸ ABCB11 O95342 1/20 0.43
▸ NR3C1 P04150 1/20 0.43
▸ RARG P13631 1/20 0.43
▸ CNR1 P21554 1/20 0.43
▸ OPRK1 P41145 1/20 0.43
▸ NR1H2 P55055 1/20 0.43
▸ PPARA Q07869 1/20 0.43
▸ NR1H3 Q13133 1/20 0.43
▸ NR1I3 Q14994 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23011535 1.00 ALDH1A1 (0.50) ALDH1A1MAPK1L3MBTL1SLC15A1CYP1A2
SCHEMBL22862307 0.91 ALDH1A1 (0.50) ALDH1A1MAPK1L3MBTL1CYP1A2CYP2C9
SCHEMBL23011534 0.89 ALDH1A1 (0.47) ALDH1A1MAPK1L3MBTL1SLC15A1CYP1A2
SCHEMBL19749931 0.87 ALDH1A1 (0.51) ALDH1A1MAPK1L3MBTL1SLC15A1CYP1A2
SCHEMBL21555767 0.87 ALDH1A1 (0.51) ALDH1A1MAPK1L3MBTL1SLC15A1CYP1A2
SCHEMBL22424808 0.87 ALDH1A1 (0.51) ALDH1A1MAPK1L3MBTL1SLC15A1CYP1A2
SCHEMBL23011540 0.86 PPID (0.46) ALDH1A1MAPK1L3MBTL1CYP1A2CYP2C9
SCHEMBL21284322 0.86 PPID (0.46) ALDH1A1MAPK1L3MBTL1CYP1A2CYP2C9
SCHEMBL19749933 0.86 ALDH1A1 (0.48) ALDH1A1MAPK1L3MBTL1SLC15A1CYP1A2
SCHEMBL2679260 0.85 ALDH1A1 (0.50) ALDH1A1MAPK1L3MBTL1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11667673-B2 Therapeutically active compounds and their methods of use SERVIER PHARMACEUTICALS LLC (US) 2023-06-06 — — US disclosed
US-20230051773-A1 TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF AXIAL THERAPEUTICS, INC. (US) 2023-02-16 — — US disclosed
US-11021515-B2 Therapeutically active compounds and their methods of use AGIOS PHARMACEUTICALS, INC. (US) 2021-06-01 — — US disclosed
US-20210024575-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC 2021-01-28 — — US disclosed
US-20200339626-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC 2020-10-29 — — US disclosed
US-10717764-B2 Therapeutically active compounds and their methods of use AGIOS PHARMACEUTICALS, INC. (US) 2020-07-21 — — US disclosed
US-10689414-B2 Therapeutically active compounds and their methods of use AGIOS PHARMACEUTICALS, INC. (US) 2020-06-23 — — US disclosed
US-10640534-B2 Therapeutically active compositions and their methods of use AGIOS PHARMACEUTICALS, INC. (US) 2020-05-05 — — US disclosed
US-20190315802-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC 2019-10-17 — — US disclosed
US-20190023737-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC 2019-01-24 — — US disclosed
US-20180194802-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC 2018-07-12 — — US disclosed
US-9850277-B2 Therapeutically active compositions and their methods of use AGIOS PHARMACEUTICALS, INC. (US) 2017-12-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200339626-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE IDH1, IDH3B, IDH3A ALDH1A1 413/4885MAPK1 4028/4885L3MBTL1 952/4885
US-11021515-B2 Therapeutically active compounds and their methods of use IDH1, IDH3B, IDH3A ALDH1A1 413/4885MAPK1 4028/4885L3MBTL1 952/4885
US-10689414-B2 Therapeutically active compounds and their methods of use IDH1, IDH3B, IDH3A ALDH1A1 413/4885MAPK1 4028/4885L3MBTL1 952/4885
US-20210024575-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE IDH1, IDH3B, IDH3A ALDH1A1 413/4885MAPK1 4028/4885L3MBTL1 952/4885
US-20230051773-A1 TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF TLR2, TLR3, TLR4 ALDH1A1 4063/4885MAPK1 749/4885L3MBTL1 4145/4885
US-11667673-B2 Therapeutically active compounds and their methods of use IDH1, IDH3B, IDH3A ALDH1A1 413/4885MAPK1 4028/4885L3MBTL1 952/4885
US-20180194802-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE IDH1, IDH3B, IDH3A ALDH1A1 646/4885MAPK1 4496/4885L3MBTL1 1367/4885
US-10640534-B2 Therapeutically active compositions and their methods of use IDH1, IDH3B, IDH3A ALDH1A1 646/4885MAPK1 4496/4885L3MBTL1 1367/4885
US-10717764-B2 Therapeutically active compounds and their methods of use IDH1, IDH3B, IDH3A ALDH1A1 413/4885MAPK1 4028/4885L3MBTL1 952/4885
US-20190023737-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE IDH1, IDH3B, IDH3A ALDH1A1 413/4885MAPK1 4028/4885L3MBTL1 952/4885
US-20190315802-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE IDH1, IDH3B, IDH3A ALDH1A1 413/4885MAPK1 4028/4885L3MBTL1 952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.